Clinical Trials Browser

Ovarian Neoplasms × Bevacizumab × 30 days × Clear all

NCT02839707 2026-03-18

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2/3 Active not recruiting

444 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT05231122 2026-03-16

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Phase 2/3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06824467 2026-03-13

TroFuse-022

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07318558 2026-03-13

TroFuse-021

Phase 3 Recruiting

Ovarian Neoplasms

NCT07470853 2026-03-13

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

Phase 1 Recruiting

Ovarian Neoplasms, Endometrial Neoplasms

NCT04931342 2026-03-10

BOUQUET

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

Phase 3 Active not recruiting

643 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

Phase 1/2 Not yet recruiting

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT06819007 2026-03-05

DO-01

Phase 3 Recruiting

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT06083844 2026-03-04

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Phase 2 Recruiting

Ovarian Neoplasms

NCT05579366 2026-03-03

RAINFOL-01

Phase 1/2 Recruiting

BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07225270 2026-03-03

RAINFOL-04

Phase 3 Recruiting

Ovarian Neoplasms

NCT05797168 2026-03-02

FONTANA

Phase 1/2 Recruiting

GynecologicThoracic

Adenocarcinoma of Lung, Ovarian Neoplasms, Endometrial Neoplasms

NCT05739981 2026-02-27

MRD

Phase 1/2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05445778 2026-02-23

GLORIOSA

Phase 3 Recruiting

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms